BRPI0608328A2 - uso de lactobacillus rhamnosus gg para tratamento, prevenção ou redução de inflamação sistêmica em um bebê alimentado com fórmula - Google Patents

uso de lactobacillus rhamnosus gg para tratamento, prevenção ou redução de inflamação sistêmica em um bebê alimentado com fórmula

Info

Publication number
BRPI0608328A2
BRPI0608328A2 BRPI0608328-5A BRPI0608328A BRPI0608328A2 BR PI0608328 A2 BRPI0608328 A2 BR PI0608328A2 BR PI0608328 A BRPI0608328 A BR PI0608328A BR PI0608328 A2 BRPI0608328 A2 BR PI0608328A2
Authority
BR
Brazil
Prior art keywords
formula
prevention
reduction
systemic inflammation
treatment
Prior art date
Application number
BRPI0608328-5A
Other languages
English (en)
Inventor
Robert J Mcmahon
Josef Neu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0608328A2 publication Critical patent/BRPI0608328A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

USO DE LACTOBACILLUS RHAMNOSUS GG PARA TRATAMENTO, PREVENçãO OU REDUçãO DE INFLAMAçãO SISTêMICA EM UM BEBê ALIMENTADO COM FóRMULA. A presente invenção refere-se ao uso de LGG na produção de um medicamento para o tratamento, a prevenção ou a redução de inflamação sistêm iça em um bebê alimentado por fórmula.
BRPI0608328-5A 2005-04-15 2006-03-22 uso de lactobacillus rhamnosus gg para tratamento, prevenção ou redução de inflamação sistêmica em um bebê alimentado com fórmula BRPI0608328A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/106,793 US20060233752A1 (en) 2005-04-15 2005-04-15 Method for treating or preventing systemic inflammation in formula-fed infants
PCT/US2006/010321 WO2006113033A1 (en) 2005-04-15 2006-03-22 Use of lactobacillus rhamnosus gg for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant

Publications (1)

Publication Number Publication Date
BRPI0608328A2 true BRPI0608328A2 (pt) 2009-12-29

Family

ID=36636335

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608328-5A BRPI0608328A2 (pt) 2005-04-15 2006-03-22 uso de lactobacillus rhamnosus gg para tratamento, prevenção ou redução de inflamação sistêmica em um bebê alimentado com fórmula

Country Status (11)

Country Link
US (1) US20060233752A1 (pt)
EP (1) EP1871401A1 (pt)
KR (1) KR20070122480A (pt)
CN (1) CN101146544A (pt)
BR (1) BRPI0608328A2 (pt)
CA (1) CA2604842A1 (pt)
MX (1) MX2007012530A (pt)
NO (1) NO20074550L (pt)
RU (1) RU2007137993A (pt)
TW (1) TW200724146A (pt)
WO (1) WO2006113033A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258823A1 (en) * 2006-12-08 2009-10-15 George Caroline L S Composition and methods for the prevention and treatment of gastrointestinal infections
MX2009008875A (es) * 2007-02-28 2009-08-28 Mead Johnson Nutrition Co Producto que contiene probiotico inactivado para niños o infantes.
EP1974734A1 (en) † 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
US8445426B2 (en) 2009-02-02 2013-05-21 Valio Ltd. Peptides and methods for producing them
US20110070334A1 (en) * 2009-09-20 2011-03-24 Nagendra Rangavajla Probiotic Stabilization
US20140093614A1 (en) * 2009-09-20 2014-04-03 Mead Johnson Nutrition Company Probiotic stabilization
US10980269B2 (en) * 2016-12-12 2021-04-20 Mead Johnson Nutrition Company Protein hydrolysates and methods of making same
CN110122877B (zh) * 2018-02-09 2022-12-23 深圳华大基因农业控股有限公司 鼠李糖乳杆菌及其用途
CN108715822B (zh) * 2018-06-13 2021-09-03 吉林省农业科学院 一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840318A (en) * 1993-05-11 1998-11-24 Immunom Technologies, Inc. Methods and compositions for modulating immune systems of animals
JPH092959A (ja) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd ＩｇＥ抗体産生抑制剤および抗アレルギー剤
US6203797B1 (en) * 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
US6696057B1 (en) * 1999-09-22 2004-02-24 Lacpro Industries, Inc. Composition and method for treatment of gastrointestinal disorders and hyperlipidemia
JP3853673B2 (ja) * 2001-03-09 2006-12-06 森永乳業株式会社 Ｃ型慢性肝炎治療剤

Also Published As

Publication number Publication date
US20060233752A1 (en) 2006-10-19
KR20070122480A (ko) 2007-12-31
CN101146544A (zh) 2008-03-19
WO2006113033A1 (en) 2006-10-26
CA2604842A1 (en) 2006-10-26
MX2007012530A (es) 2008-02-12
EP1871401A1 (en) 2008-01-02
RU2007137993A (ru) 2009-05-20
TW200724146A (en) 2007-07-01
NO20074550L (no) 2007-11-13

Similar Documents

Publication Publication Date Title
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
BRPI0616960B8 (pt) uso de lactobacilo para o tratamento de infecções virais
BRPI0512584A (pt) método para prevenir ou tratar infecções respiratórias e otite média em lactentes
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
WO2008070593A3 (en) Variant target binding agents and uses thereof
BRPI0612309B8 (pt) compostos e composições farmacêuticas antivirais
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
WO2008067982A3 (en) Use of carrageenan for treating rhinovirus infections
WO2007131047A3 (en) Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds
MY150931A (en) Substituted oxazolidinones and their use
WO2008090209A3 (en) Use of glucopyranosyloxy- pyrazoles for preventing and treating neurodegenerative disorders
NO20074550L (no) Anvendelse av Lactobacillus Rhamnosus GG for behandling, forebygging eller reduksjon av systemisk inflamasjon hos et spebarn matet med morsmelkerstatning
NO20083901L (no) Fiksert-dose-assosiasjon av fytat og sink
TW200716146A (en) Method for treating or preventing systemic inflammation in formula-fed infants
UA94781C2 (ru) Применение йота-каррагенана для профилактики или терапевтического лечения риновирусной инфекции
WO2007108004A3 (en) S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
WO2006089664A3 (de) Heterocyclylamid-substituierte imidazole
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2007016450A3 (en) Methods for treating or preventing reactivation of a latent herpesvirus infection
BRPI0503827A (pt) métodos para prevenir ou tratar infecções respiratórias em lactentes
IL186092A (en) Use of azithromycin for the preparation of a topical eye medication for the treatment and prevention of tuberculosis infections by chalamydia trachomatis
PL1837029T3 (pl) Kompozycja farmaceutyczna do zapobiegania i leczenia przeziębień
NO20074767L (no) Anvendelse av rimonabant for fremstilling av medikamenter som kan anvendes i forebygging og behandling av type 2 diabetes
UA27643U (en) Method for treatment of community-acquired pneumonia in children

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]